Report of Foreign Issuer (6-k)
15 May 2020 - 6:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of May 2020
Commission
File Number 001-38370
CollPlant
Biotechnologies Ltd.
(Exact
name of registrant as specified in its charter)
4
Oppenheimer St, Weizmann Science Park
Rehovot
7670104, Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This
Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163)
and Form F-3 (File No. 333-229486 and 333-228054), to be a part thereof from the date on which this report is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.
On
May 14, 2020, CollPlant Biotechnologies Ltd.
(the “Company”) convened an extraordinary general meeting of shareholders (the “Meeting”) at which the
Company’s shareholders approved each of the four proposals brought before the Meeting in accordance with the majority required
for each proposal.
Each
of those proposals was described in the Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting
of Shareholders, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange
Commission on April 7, 2020.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
|
|
|
Date:
May 14, 2020
|
By:
|
/s/
Eran Rotem
|
|
|
Name:
Eran Rotem
|
|
|
Title:
Deputy CEO and Chief Financial Officer
|
2
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Apr 2024 to May 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From May 2023 to May 2024